Brief: Poxel Presents New Preclinical Results For PXL770

Poxel SA

12/02/2020 08:29

Feb 12 (Reuters) - POXEL SA  POXEL.PA :
    * POXEL PRESENTS NEW PRECLINICAL PROOF-OF-CONCEPT RESULTS
FOR
PXL770 AT THE 3RD ANNUAL GLOBAL NASH CONGRESS
    * POXEL SA SAYS CLINICAL RESULTS FROM PXL770 PK/PD TRIAL AND
PHASE
2A STUDY EXPECTED IN 2Q AND 3Q OF 2020, RESPECTIVELY
    * PXL770, OBSERVED TO REDUCE LIVER INFLAMMATORY CELLS, WHICH
MAY
CONTRIBUTE TO AN IMPROVEMENT OF FIBROGENESIS, IN A PRECLINICAL
NASH MODEL
    * WE NEAR UPCOMING CLINICAL READOUTS FROM OUR PXL770 PK/PD
TRIAL
AND PHASE 2A STUDY
    * CLINICAL READOUTS FROM OUR PXL770 PK/PD TRIAL AND PHASE 2A
STUDY, WHICH ARE CURRENTLY EXPECTED IN SECOND AND Q3 OF 2020,
RESPECTIVELY

Source text for Eikon:  ID:nBw4NHzGsa 
Further company coverage:  POXEL.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))